Eric Benevich - 10 Dec 2024 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Reporting relationship: Director
Issuer ticker: ATYR
Reported as of: 10 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Dec 2024, 16:15:23 UTC
Prior SEC filing: 17 Apr 2024
Next SEC filing: 04 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Nancy E. Denyes, as Attorney-in-Fact

Key filing fact

Eric Benevich filed Form 4 for aTYR PHARMA INC (ATYR) on 12 Dec 2024.

Key facts

This page summarizes Eric Benevich's Form 4 filing for aTYR PHARMA INC (ATYR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Dec 2024, 16:15.

Change

Previous filing in this sequence was filed on 17 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATYR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 10 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $3.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning January 10, 2025, such that this option will be fully exercisable on December 10, 2027, subject to the recipient's continued service on the Issuer's Board of Directors.